Physician profile
Pascal Ngongmon
NPI 1861739518
$24,598.19
in general payments reported to CMS, 2019-2025
13 companies · $17K in 2025
The $17K reported for 2025 was more than what 96% of Sleep Medicine (Internal Medicine) providers received nationally (typical 2025 total: $447).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $147 · 2020: $57.77 · 2021: $18.56 · 2022: $95.72 · 2023: $224 · 2024: $7,238 · 2025: $17K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $16K · Consulting Fee: $4,375 · Travel and Lodging: $2,575 · Food and Beverage: $736 · Education: $143.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $16,450.00 |
| Consulting Fee | $4,375.00 |
| Travel and Lodging | $2,574.87 |
| Food and Beverage | $736.21 |
| Education | $142.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $23,864.33 | 2024-2025 | Zepbound |
| Jazz Pharmaceuticals INC. | $286.09 | 2019-2025 | |
| Vivus LLC | $124.97 | 2023 | Qsymia |
| Harmony Biosciences LLC | $69.78 | 2020-2023 | Wakix |
| Janssen Pharmaceuticals, INC | $53.00 | 2022-2023 | Xarelto |
| Vanda Pharmaceuticals INC. | $41.55 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $34.18 | 2023 | Camzyos |
| Resmed Corp | $26.32 | 2019 | |
| Novartis Pharmaceuticals Corporation | $20.54 | 2022 | |
| Gilead Sciences, INC. | $20.46 | 2022 | |
| Ferring Pharmaceuticals INC. | $19.68 | 2023 | Rebyota |
| Astrazeneca Pharmaceuticals Lp | $18.73 | 2022 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $18.56 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Pascal Ngongmon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.